Advancing LNP Characterization for Drug Delivery

Join our experts as they bring together cutting-edge science and strategic manufacturing insights to explore the full journey of lipid nanoparticles (LNPs), from groundbreaking research to real-world applications.

Prof. Peer will explore the progression and applications of LNPs, from targeting cancer cells to developing the first bacterial mRNA vaccine. He will also discuss personalized medicine using LNPs for precise cell delivery. Tristan Kovačič will complement Peer’s work by addressing the complexities of manufacturing and ensuring quality control for LNP-based biopharmaceuticals. He will reveal how advanced analytical techniques, like monolithic chromatography, streamline workflows and guarantee proper handling of diverse cargo formulations critical for in vivo CAR-T, CRISPR and vaccine applications.

This webinar highlights not just the exciting developments in LNP technology but also the critical transition from research to real-world therapeutic applications. Secure your access to insights on cutting-edge LNPs and strategic manufacturing solutions for next-generation medicines.

Dan Peer is a Professor and the Director of the Laboratory of Precision NanoMedicine at Tel Aviv University. Prof. Peer pioneered the use of RNA interference (RNAi) as drug discovery tools in immune cells. In addition, his lab was the first to show systemic, cell specific delivery of modified mRNA in animals, and the first to show systemic, high efficiency, cell specific, therapeutic genome editing in cancer. Recently, his lab showed the first bacterial mRNA vaccine that opened a new potential field of increasing the arsenal of vaccines against antibiotic resistance strains.

Tristan Kovačič is a scientist in the Process Analytics Development Department at Sartorius BIA Separations and a PhD student in Computational Chemistry at the University of Maribor. He holds an MSci degree in Chemistry from Imperial College London. He has experience in the pharmaceutical and biotech industries, focusing on process development and analytics for non-viral drug delivery systems and active pharmaceutical ingredients.